-
Express results in positive proof-of-concept clinical trials for innovative therapies targeting multiple drivers of NASH
Time of Update: 2022-02-20
▎89bio, the editor of WuXi AppTec's content team, recently announced that its investigational therapy pegozafermin (formerly BIO89-100) for the treatment of nonalcoholic steatohepatitis (NASH) has been obtained in a phase 1b/2a proof-of-concept clinical trial.
-
The clinical results of the express dual mechanism PD-L1 monoclonal antibody are positive
Time of Update: 2022-02-20
▎WuXi AppTec Content Team Editor On January 25, 2022, Checkpoint Therapeutics announced that the anti-PD-L1 antibody cosibelimab has achieved positive results in a clinical trial that supports registration .
"Reference: [1] Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma.
-
blood: HLA association, HLA expression of somatic cell loss and clinical results in immune aplastic anemia.
Time of Update: 2021-12-26
A research team examined the somatic cell loss of HLA class I alleles and correlated HLA genotypes related to HLA loss and mutation with the clinical manifestations and results of 544 AA patients after immunosuppressive treatment .
-
Express delivery of 100% of patients achieved complete remission, and the Phase 2 clinical results of the oncolytic virus/PD-1 antibody combination are positive
Time of Update: 2021-12-07
▎The content team editor of WuXi AppTec recently, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, combined with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer , These patients did not respond to BCG treatment .
-
Express 100% of patients get objective relief, and the latest clinical results of ready-to-use natural killer cell therapy are positive
Time of Update: 2021-12-05
▎Editor of WuXi AppTec Content Team On November 22, 2021, Affimed announced that its cord blood-derived natural killer cell therapy was pre-combined with the innate cell engager (ICE) AFM13.
-
Express significantly reduces inflammation indicators in patients with multiple sclerosis
Time of Update: 2021-11-05
▎Editor of WuXi AppTec content team Recently, Merck KGaA of Germany announced the post-mortem analysis data of a phase 2 clinical trial of the brain-permeable BTK inhibitor evobrutinib for the treatment of patients with multiple sclerosis (MS) .
-
Express significantly slows down the disease progression of breast cancer patients, and the phase 3
Time of Update: 2021-11-04
▎Editor of WuXi AppTec Content Team On October 20, 2021, Menarini Group and Radius Health announced that selective estrogen receptor degradant (SERD) elacestrant has obtained positive results in a phase 3 clinical trial .
-
Express for drug-resistant bacterial infections, innovative antibiotic compound therapy Phase 3 clinical results are positive
Time of Update: 2021-11-04
▎Editor of WuXi AppTec content team On October 19, 2021, Zai Lab and Entasis Therapeutics announced that the antibiotic combination therapy sulbactam-durlobactam (SUL-DUR) has obtained positive results in a phase 3 clinical trial .
-
Express treatment of fatal childhood immunodeficiency, initial clinical trial results of innovative gene therapy are positive
Time of Update: 2021-11-04
▎WuXi AppTec content team editor A few days ago, Rocket Pharmaceuticals announced that its research gene therapy RP-L201 has obtained positive interim data in a phase 1/2 clinical trial for the treatment of leukocyte adhesion deficiency type I (LAD-I) .
-
Express delivery of more than half of the symptoms of vitiligo patients improved by 50
Time of Update: 2021-10-22
▎The content team editor of WuXi AppTec recently, Incyte announced the complete results of a pivotal Phase 3 clinical trial of its topical JAK inhibitor ruxolitinib cream (ruxolitinib, English trade name Opzelura) in the treatment of patients with vitiligo over 12 years old .
-
Express precise treatment of cholangiocarcinoma, preliminary clinical results of highly specific FGFR2 inhibitors are positive
Time of Update: 2021-10-22
▎Editor of WuXi AppTec's content team recently, Relay Therapeutics announced that its highly specific FGFR2 oral inhibitor RLY-4008 has achieved positive mid-term in its phase 1 clinical trial in patients with FGFR2 variant cholangiocarcinoma and a variety of other solid tumors.
-
Express bicyclic peptides accurately deliver cytotoxic drugs and treat bladder cancer and ovarian cancer with positive clinical results
Time of Update: 2021-10-22
▎Bicycle Therapeutics, editor of WuXi AppTec's content team, announced today that two new-generation bicyclic peptide-conjugated toxins have shown positive anti-cancer activity in phase 1 clinical trials .
-
Express significantly improves the vision of patients with diabetic macular edema, and the Phase 2
Time of Update: 2021-10-21
▎Editor of WuXi AppTec's content team recently, Oxurion announced that THR-149, an investigational therapy jointly developed with Bicycle Therapeutics, has obtained positive results in a phase 2 clinical trial for the treatment of patients with diabetic macular edema (DME) .
-
Express gene editing to create "ready-to-use" CAR-T therapy, phase 1 clinical trial results are positive
Time of Update: 2021-10-21
▎The content team editor of WuXi AppTec today, CRISPR Therapeutics announced that the allogeneic CAR-T cell therapy CTX110, modified with CRISPR gene editing technology, has achieved positive safety and efficacy in a phase 1 clinical trial for the treatment of CD19-positive B-cell cancers Result .
-
Express delivery and influenza vaccination at the same time, Pfizer 20-valent pneumococcal conjugate vaccine Phase 3 clinical results are positive
Time of Update: 2021-10-10
▎ WuXi AppTec content team editor September 29, 2021, Pfizer announced that a phase 3 clinical trial of the 20-valent pneumococcal conjugate vaccine Prevnar 20 has achieved positive top-line results .